{"id":63365,"date":"2025-01-07T12:05:05","date_gmt":"2025-01-07T12:05:05","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/01\/07\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/"},"modified":"2025-01-07T12:05:05","modified_gmt":"2025-01-07T12:05:05","slug":"micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/","title":{"rendered":"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants"},"content":{"rendered":"<div>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><em>New $7.5M grant builds on prior funding and follows positive phase 1\/2 data recently published in The Lancet <\/em><\/li>\n<li style=\"text-align:justify;\"><em>Gates Foundation\u2019s David Robinson joins Micron Biomedical\u2019s Board as an observer to support the accelerated commercialization of Micron\u2019s technology <\/em><\/li>\n<\/ul>\n<p align=\"justify\">ATLANTA, Jan.  07, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ih9ixrTG_u78PrQEkEUlYUoXESPwMqCoYk5_ubdTmSRJLXLfe3Q5Jp48ZWVeROmTMoPE7Db3k0fdNCwOdBFKd36HADclPuWn5Yr5Zr4y4sM=\" rel=\"nofollow\" target=\"_blank\" title=\"Micron Biomedical\">Micron Biomedical<\/a>, a life science company developing the world\u2019s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced the company secured a $7.5 million grant from the Bill &amp; Melinda Gates Foundation that brings total grant funding from the organization to $43 million.<\/p>\n<p align=\"justify\">The grant will support Micron\u2019s efforts in increasing access to measles-rubella (MR) vaccine and this latest tranche will fund ongoing manufacturing scale-up efforts and activities to support a phase 2 trial in infants. David Robinson, Deputy Director, Vaccine Development &amp; Surveillance, Gates Foundation, will join Micron Biomedical\u2019s board as an observer.<\/p>\n<p align=\"justify\">\u201cThe continued funding support from the Bill &amp; Melinda Gates Foundation to aid our work to increase access to the MR vaccine has been pivotal in Micron Biomedical\u2019s progress toward making lifesaving and life-changing life science innovations more available and accessible,\u201d said Steven Damon, CEO of Micron Biomedical. \u201cThis grant builds on previous funding that helped generate the positive phase 1\/2 data that demonstrated our ability to overcome challenges getting preventive treatment to people who currently lack access and will accelerate our efforts toward commercialization so that we can help to make critical pharmaceuticals more easily accessible and available.\u201d<\/p>\n<p align=\"justify\">The eradication of measles is possible because the measles vaccine is highly effective and there is no known animal reservoir of the disease, yet inequitable immunization coverage persists. A study recently published in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lmJK_GkFjNxEeY8ZEKOM_iR7yA4QsHpt9crEsAM8VUrCRuYTRHj-Bu9QMvjJWDiVnKiXUa28R03RXyFdoDU2Iq3z4LtRi3sgrE-ga-9qD9gkFtUc234OAxEkdAHF2oJgp3ArOlJVjGNtvsJLQDL_EMXU4aiTABlj36sfcjuv73k=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><em><u>The Lancet<\/u><\/em><\/a> that involved Micron\u2019s needle-free microarray technology was the first to demonstrate the safety, immunogenicity, and acceptability of a vaccine delivered to children as young as 9 months old via any needle-free microarray technology. The research involved the leading commercially available MR vaccine.<\/p>\n<p align=\"justify\">Measles remains a serious global health risk that kills an estimated three children per 1,000 that contract the disease<sup>1<\/sup>, with a disproportionate impact in areas where access to vaccines is complicated by limited clinicians, refrigeration and centralized healthcare. Previous grants from the Bill &amp; Melinda Gates Foundation funded the phase 1\/2 trial and funded the development of commercial manufacturing equipment that will produce the MR vaccines at global scale.<\/p>\n<p align=\"justify\">According to the World Health Organization, children should be vaccinated against measles between the ages of 9 and 12 months, then again between 15\u201318 months<sup>2<\/sup>. However, common infrastructure-related barriers preclude millions globally from accessing life-saving vaccines and therapeutics. In low- and middle-income countries, measles remains a leading cause of death, primarily due to limited access to vaccines that require refrigeration during transport and storage and clinicians to administer them. Micron is developing a needle-free version of the MR vaccine based on its microarray technology which reduces the need for a cold chain and could enable a non-clinician to administer the vaccine. Micron\u2019s MR vaccine is administered by applying the technology to the skin and pressing a button that confirms administration. The administration of the vaccine is virtually painless.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n<p align=\"justify\">Micron\u2019s technology has been recognized for its potential to achieve positive global impact and be <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eMvVs3LPwAxFH76uds8mpN0oREJA-agUpb48Z8j9iZM6OdsV_FpB-HpghwzvTGi5yAfeeQd3Nr3FWU4Fq1JEgmidA4a3neT-S25PR93uB3Tz34TBv3QbRxdI92ZU9wWu01M9JPftUMDYORPPkmjqjsx6zM_YNRBCMfYljZ4n6MA=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>game-changing<\/u><\/a> in hard-to-reach settings. In addition to improving access to vaccines and therapeutics in low- and middle-income countries, Micron\u2019s technology has an opportunity to improve health globally as the evidence reflects that patient reluctance to receive injectable medicine can lead to delayed therapy, treatment avoidance, and vaccine hesitancy in higher income countries. The technology\u2019s broad impact also includes US national health security, as well as veteran and military health.<\/p>\n<p align=\"justify\"><strong>About Micron Biomedical <\/strong><br \/>Micron Biomedical is the leader in dissolvable microarray-based, drug and vaccine administration technology. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron&#8217;s technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and\/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and\/or receives funding from private and public entities including pharmaceutical and biotech companies, the Bill &amp; Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH and the Georgia Research Alliance.<\/p>\n<p align=\"justify\">For more information visit www.micronbiomedical.com.<\/p>\n<p align=\"justify\"><strong>Media Inquiries:<\/strong><br \/>Shira Derasmo<br \/>917-280-2497<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bl25zlri4SGDFVsiSqAR-U0vBRntDHk28XjRzJSV7dOOAqYbaHhP-vTIZ4nbE5MulTLcExwxLNh_yaLWT_kFKjKgXSnfolHT_-Xceq8ZfPE=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>pr@micronbiomedical.com<\/u><\/a><\/p>\n<p align=\"justify\"><strong>Partnership Inquiries <\/strong><br \/>Micron Biomedical, Inc<br \/>bd@micronbiomedical.com<\/p>\n<p><sup><sup>___________________________<br \/>1<\/sup><\/sup> Centers for Disease Control, May 2024 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j_5nQqMOWQPHbg_FW075URmqWxvntT9WQjgLcopM0A0QQkQ9YpZBggvF26u0qRv4sROthb813IYbllDpPZCRgUOQATMpzXqHzu-tby81G7t5wA3KUg1JZbfMOlQV-HwgyJxjBL_S1MZiyEG6YHZAZqnNrV8oAPdXWk6MCkUipjI-qBxLzqpM3myNaK6dwfKC\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.cdc.gov\/measles\/signs-symptoms\/index.html<\/u><\/a> <br \/><sup><sup>2<\/sup><\/sup> World Health Organization, Aug 2023 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j_5nQqMOWQPHbg_FW075UcRh2m-ZqymXGVCtH702I3GyPmrniT8TvE0g5s2h16TtB2qHcfvLPA9yzQjGlN2IH2KV68sHNm5oT8ywtwYMChkm6ci8e0dMxdUV2zFtI_b0OwZ8JZQIblDWk06EPmtPKO6gSuDdm98AUEQle376JkeMhdp1cy6qsmskzpv6Q3f1\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/measles<\/u><\/a>\u00a0\u00a0<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2M4Njc2OWItZDczNi00ZWRiLTliOTAtMmRmMWUzODQzYjlkLTUwMDEzMTQ5MQ==\/tiny\/Micron-Biomedical.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New $7.5M grant builds on prior funding and follows positive phase 1\/2 data recently published in The Lancet Gates Foundation\u2019s David Robinson joins Micron Biomedical\u2019s Board as an observer to support the accelerated commercialization of Micron\u2019s technology ATLANTA, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Micron Biomedical, a life science company developing the world\u2019s first needle-free [&#8230;]\n","protected":false},"author":1,"featured_media":63366,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-63365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants\" \/>\n<meta property=\"og:description\" content=\"New $7.5M grant builds on prior funding and follows positive phase 1\/2 data recently published in The Lancet Gates Foundation\u2019s David Robinson joins\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T12:05:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Micron-Biomedical.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants\",\"datePublished\":\"2025-01-07T12:05:05+00:00\",\"dateModified\":\"2025-01-07T12:05:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\"},\"wordCount\":798,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\",\"name\":\"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-01-07T12:05:05+00:00\",\"dateModified\":\"2025-01-07T12:05:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/","og_locale":"en_US","og_type":"article","og_title":"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants","og_description":"New $7.5M grant builds on prior funding and follows positive phase 1\/2 data recently published in The Lancet Gates Foundation\u2019s David Robinson joins","og_url":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-01-07T12:05:05+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Micron-Biomedical.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants","datePublished":"2025-01-07T12:05:05+00:00","dateModified":"2025-01-07T12:05:05+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/"},"wordCount":798,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/","url":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/","name":"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-01-07T12:05:05+00:00","dateModified":"2025-01-07T12:05:05+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/micron-biomedical-secures-43-million-in-total-grant-support-to-improve-coverage-of-measles-and-rubella-vaccine-and-accelerate-worlds-first-phase-2-trial-of-needle-free-drug-and-vaccine-techn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World\u2019s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=63365"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63365\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/63366"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=63365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=63365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=63365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}